 The coronavirus pandemic was clearly 2020's top story, impacting not just the medtech and healthcare industries but nearly every aspect of the U.S. and global economies.
Medtech headlines ranged from COVID-19 tests being developed and authorized at an unprecedented pace to the widespread shutdown of elective care and the rush to recapture procedure volume losses. Companies pulled 2020 guidances and adjusted strategies to best manage the pandemic — some faced more significant losses than others.
Regulators also felt the strain of navigating 2020, with COVID-19 priorities stretching the resources of FDA’s CDRH and the EU alike.
The pandemic, however, was not a financial negative for all in the medtech space. COVID-19 offerings boosted companies like Abbott throughout the year, and a boom in virtual care has accelerated market opportunities for larger traditional companies and smaller, tech-focused players.
The 11 stories included below are as published; some details may have changed.
As we enter into 2021, we kindly ask that you consider sharing our newsletter with your teammates and colleagues, to help them stay more informed in the new year. Share this link to get them signed up: https://www.medtechdive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316
We are publishing one last newsletter on Dec. 30 looking at top medtech trends in 2020, and then we will be back full time on Jan. 4.
Thank you for reading!
 Ricky Zipp
Reporter, MedTech Dive
E-mail | Twitter The updates from the major U.S. clinical labs come days after FDA OK'ed the use of lab developed tests that have not yet received emergency use authorization. |
The agency alert, prompted by reports from nursing homes and other settings, comes a day after data emerged raising concerns about the ability of a Quidel test to detect asymptomatic cases. |
BinaxNOW requires a prescription and a telehealth service to take users through collection. However, public health experts question why prescriptions are being required at all for such tests. |
The company is aiming to more than double its manufacturing capacity as GE, Getinge, Philips and others outside of healthcare commit to boosting worldwide supply of the potentially lifesaving machines. |
The medtech received a "partial termination" notice and will not deliver 30,700 remaining ventilators to the Strategic National Stockpile, a month after a House panel called for a probe into the roughly $647 million contract. |
After a "massive increase" in work due to the pandemic, the device center anticipates continuing to manage coronavirus projects while also focusing on MDUFA V and new programs. |
UPDATED The European Commission listed a 13th notified body designated for Medical Device Regulation-related work in its official database Saturday, the first new firm announced in over a month and the fifth based in Germany. |
Wall Street expects declines in elective care to continue as coronavirus cases keep rising. However, a more widespread rollout of vaccines could spur momentum later in the year. |
UPDATED Breaking with a trend of smaller medtech deal values in 2020, the pact will see radiation oncology equipment and software maker Varian Medical Systems operate as an independent company under Siemens Healthineers. |
The acquisition of Digital Surgery comes as Medtronic inches its own soft tissue robot toward competition with Intuitive's da Vinci. |
UPDATED Shares fell 10% after a voluntary recall led Boston Scientific to end the product line entirely. The surprise move gives Medtronic and Edwards Lifesciences the opportunity to gain back ground in the near term. | | |
0 Comments